Sophonix Raises ￥100M in Series B Financing, Focusing on IVD

According to VCBeat, Beijing Meilian Tyco Biotechnology Co., Ltd. ("Sophonix") recently completed a ￥100 million Series B financing, led by Zero2IPO Asset Management, with participation from Delian Capital, Anlong Capital, GoldTech Capital, Mingshi Investment and existing backer ETP. Yijun Capital served as the financial adviser of the latest round. 

This financing is also one of the largest single financing rounds in the field of point-of-care-testing (POCT) based on chemiluminescence in China so far. Proceeds from this round will be used for product development and upgrade, the construction of marketing system, localization, improvement of logistics and warehousing, after-sales services, and marketing, and further exploration in the market segment and overseas market.

Sophonix was established in July 2017 and is located in the Beijing Economic and Technological Development Zone. The company has established dual research and development centers in California and Beijing, China. 

Sophonix is a modern biotechnology company dedicated to in vitro diagnostics (IVD), integrating research and development, production, sales, and service. The company has a complete product portfolio of independent intellectual property rights, systematic instruments and reagents, and its products cover pathological diagnosis and immunodiagnosis, with the product line for molecular diagnosis under construction.

Centering on the application scenarios and combining with the advanced testing platform, Sophonix provides POCT solutions that are multi-directional, repeatable and accurate. With the trend of replacement of imported medical devices and the development of primary medical care, Sophonix will continue to explore the field of IVD, making its products including the fully automatic chemiluminescence analyzer, pathological products and molecular diagnosis products more in line with the trend of the market and the industry.

Zero2IPO Asset Management provides industrial strategy and medium & long-term asset management investment services for listed companies and family enterprises. Currently, it has managed dozens of strategic funds and family funds of listed companies over 20 billion yuan, mainly investing in growth-stage companies in healthcare, consumption upgrading, intelligent manufacturing, culture and entertainment, education and other fields.

Founded in 2011, Delian Capital specializes in the field of tech-driven industries such as high-end manufacturing, cutting-edge technologies, and healthcare. Their investments range from robotics, Smart manufacturing Semiconductor, AI, big data, enterprise services, healthcare, etc.